Aggrastat - General Information
Aggrastat prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide reversible antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation.
Pharmacology of Aggrastat
Aggrastat prevents the blood from clotting during episodes of chest pain or a heart attack, or while the patient is undergoing a procedure to treat a blocked coronary artery. It is a non-peptide antagonist of the platelet glycoprotein (GP) IIb/IIIa receptor, and inhibits platelet aggregation. When administered intravenously, tirofiban inhibits ex vivo platelet aggregation in a dose- and concentration-dependent manner. When given according to the recommended regimen, >90% inhibition is attained by the end of the 30-minute infusion. Aggrastat has been recently shown in patients with unstable angina to reduce ischemic events at 48 hours following infusion when compared to standard heparin therapy.
Aggrastat for patients
Follow all instructions for proper mixing or dilution (if necessary) and refer to the tirofiban dosing chart for the recommended IV dosing. If you have questions regarding the use of this medication, consult your pharmacist. Give this medication by vein (IV) as an initial dose (bolus dose) followed by an IV infusion as directed by your doctor. The dosage is based on your weight, medical condition, and response to therapy. Before using, check this product visually for particles or discoloration. If either is present, do not use the liquid. Learn how to store and discard needles and medical supplies safely. Consult your pharmacist.
AGGRASTAT has been studied on a background of aspirin and heparin.
The use of AGGRASTAT, in combination with heparin and aspirin, has been associated with an increase in bleeding compared to heparin and aspirin alone.
AGGRASTAT is contraindicated in patients with:
ï known hypersensitivity to any component of the product
ï active internal bleeding or a history of bleeding diathesis within the previous 30 days
ï a history of thrombocytopenia following prior exposure to AGGRASTAT
ï history of stroke within 30 days or any history of hemorrhagic stroke
ï major surgical procedure or severe physical trauma within the previous month
ï history, symptoms, or findings suggestive of aortic dissection
ï severe hypertension (systolic blood pressure >180 mmHg and/or diastolic blood pressure >110 mmHg)
ï concomitant use of another parenteral GP IIb IIIa inhibitor
ï acute pericarditis
Additional information about Aggrastat
Aggrastat Indication: For treatment, in combination with heparin, of acute coronary syndrome, including patients who are to be managed medically and those undergoing PTCA or atherectomy.
Mechanism Of Action: Aggrastat is a reversible antagonist of fibrinogen binding to the GP IIb/IIIa receptor, the major platelet surface receptor involved in platelet aggregation. Platelet aggregation inhibition is reversible following cessation of the infusion of Aggrastat.
Drug Interactions: Not Available
Food Interactions: Not Available
Generic Name: Tirofiban
Synonyms: Not Available
Drug Category: Fibrinolytic Agents; Platelet Aggregation Inhibitors
Drug Type: Small Molecule; Approved
Other Brand Names containing Tirofiban: AGG; Aggrastat; Tirofiban [BAN-INN];
Absorption: Not Available
Toxicity (Overdose): Not Available
Protein Binding: 65%
Biotransformation: Metabolism appears to be limited.
Half Life: 2 hours
Dosage Forms of Aggrastat: Solution Intravenous
Chemical IUPAC Name: (2S)-2-(butylsulfonylamino)-3-[4-(4-piperidin-4-ylbutoxy)phenyl]propanoic acid
Chemical Formula: C22H36N2O5S
Tirofiban on Wikipedia: https://en.wikipedia.org/wiki/Tirofiban
Organisms Affected: Humans and other mammals